Akari TX

NEW YORK and LONDON – Akari Therapeutics (NASDAQ:AKTX, is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive …

[Read more...] about Akari Therapeutics Announces Appointment of David Horn Solomon as CEO

NEW YORK and LONDON, August 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, …

[Read more...] about Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference

NEW YORK and LONDON, June 23, 2017 -- Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd …

[Read more...] about Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association

- Executive Chairman to Continue to Fulfill Interim CEO Duties as Board Commences Executive Search - Data Correction for Fifth Patient in Phase 2 PNH Trial for …

[Read more...] about Akari Therapeutics Announces Resignation of CEO

NEW YORK and LONDON, April 27, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a …

[Read more...] about Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”